“The existing predicament has exposed some structural weaknesses inside the EU’s medicines supply chain and also a significant dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides reported. She suggested that supply chain troubles be addressed in an EU pharmaceutical strategy anticipated being released by the end in